Physician profile
Kumar Ramdas
NPI 1780663898
$86,581.57
in general payments reported to CMS, 2019-2025
62 companies · $2,895 in 2025
The $2,895 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $41K · 2021: $22K · 2022: $3,659 · 2023: $2,287 · 2024: $2,243 · 2025: $2,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,352 · Education: $73.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,351.97 |
| Education | $73.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28,189.17 | 2019-2021 | |
| Glaxosmithkline, LLC. | $20,177.68 | 2019-2024 | Trelegy Ellipta |
| Abbvie INC. | $14,023.48 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $9,911.84 | 2019-2024 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals Lp | $2,619.39 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,465.48 | 2019-2024 | Jardiance, Synjardy |
| Lilly USA, LLC | $1,427.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $964.80 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Madrigal Pharmaceuticals | $678.61 | 2024-2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $574.80 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $537.63 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $399.94 | 2024-2025 | Gemtesa |
| Horizon Therapeutics Plc | $399.80 | 2019-2023 | Krystexxa |
| Sunovion Pharmaceuticals INC. | $351.46 | 2019-2021 | |
| Travere Therapeutics, INC. | $347.23 | 2019-2023 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $277.92 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $272.19 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.87 | 2019-2025 | Xifaxan, Trulance |
| Intra-Sana Laboratories | $246.70 | 2022-2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Dexcom, INC. | $221.93 | 2021-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $204.98 | 2019-2025 | Rexulti |
| Vifor Pharma, INC. | $204.09 | 2022-2023 | Veltassa |
| E.R. Squibb & Sons, L.L.C. | $198.06 | 2019-2025 | Cobenfy, Eliquis |
| Kowa Pharmaceuticals America, INC. | $186.55 | 2019-2024 | Zoryve, Livalo |
| Scilex Pharmaceuticals INC. | $186.08 | 2019-2025 | Ztlido |
| Astellas Pharma US INC | $177.73 | 2019-2020 | |
| Medtronic, INC. | $165.19 | 2025 | Hawkone |
| Ani Pharmaceuticals, INC. | $158.62 | 2024-2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $154.85 | 2021-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $150.60 | 2019-2020 | |
| Amarin Pharma, INC. | $129.70 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $126.18 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Phathom Pharmaceuticals, INC. | $124.99 | 2025 | Voquezna |
| Abiomed | $123.17 | 2025 | |
| Mannkind Corporation | $101.40 | 2019-2024 | Afrezza |
| Arbor Pharmaceuticals, INC. | $83.52 | 2019 | |
| Ironwood Pharmaceuticals, INC | $59.83 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $54.62 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.48 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company Ltd. | $45.76 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $42.48 | 2019-2025 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $38.40 | 2021-2023 | |
| Valeritas, INC. | $36.53 | 2019 | |
| Lundbeck LLC | $32.55 | 2023 | Rexulti |
| Embecta Corp. | $31.94 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Vanda Pharmaceuticals INC. | $31.55 | 2025 | Fanapt, Hetlioz |
| Azurity Pharmaceuticals, INC. | $30.85 | 2023-2025 | Edarbi, Edarbi |
| Exact Sciences Corporation | $30.23 | 2024 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $29.78 | 2022 | |
| Avanir Pharmaceuticals, INC. | $28.91 | 2019 | |
| Endo Pharmaceuticals INC. | $28.49 | 2019 | |
| Gilead Sciences, INC. | $27.30 | 2019-2020 | |
| Grifols USA, LLC | $23.75 | 2024 | Prolastin-C Liquid |
| Amphastar Pharmaceuticals, INC. | $18.96 | 2025 | |
| Neurelis, INC. | $16.67 | 2022 | |
| Neurocrine Biosciences, INC. | $16.23 | 2023 | Ingrezza |
| Acadia Pharmaceuticals INC | $16.16 | 2025 | Nuplazid |
| Esperion Therapeutics, INC. | $15.68 | 2024 | Nexletol |
| Mayne Pharma Commercial LLC | $14.81 | 2020 | |
| Aytu Biopharma, INC. | $14.24 | 2019 | |
| Radius Health, INC. | $13.20 | 2020 | |
| Mylan Specialty L.P. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Ramdas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.